Erschienen in:
01.08.2017 | Original Paper
Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients
verfasst von:
Dilsa Mizrak Kaya, Xiaochuan Dong, Graciela M. Nogueras-González, Yan Xu, Jeannelyn S. Estrella, Kazuto Harada, Anthony Lopez, Fatemeh G. Amlashi, Wayne L. Hofstetter, Dipen M. Maru, Quynh-Nhu Nguyen, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Jeremy J. Erasmus, Irene Thomas, Jane E. Rogers, Shumei Song, Jaffer A. Ajani
Erschienen in:
Medical Oncology
|
Ausgabe 8/2017
Einloggen, um Zugang zu erhalten
Abstract
Resectable esophageal adenocarcinoma (EAC) patients often receive chemoradiation followed by surgery. However, most patients experience recurrences. Overexpression of MTDH, an oncoprotein with multiple functions, has been found to be associated with poor prognosis in breast cancer, glioblastoma, melanoma and various gastrointestinal malignancies, but not in EAC. We sought to establish its role in resistant EAC (post-treatment residual EAC). MTDH was assessed by immunohistochemistry in resected EAC, and results were correlated with clinical outcomes. MTDH expression was detectable in 72.5% (50/69) of patients, while expression levels were high (positive) in 50.7% (35/69). Of 69 patients analyzed, 25 had no relapse and 44 patients had a relapse (8 with local–regional and 36 with distant). The median follow-up duration was 3 years (0.4–11.6). The median overall survival was not associated with MTDH status (2.79 years for MTDH-negative and 3.60 years for MTDH-positive patients, p = 0.121). In addition, MTDH was not associated with either the type of relapse (local or distant), baseline clinical stage, tumor grade, presence of signet ring cells, surgical (yp) stage, percentage of residual EAC or presence of lymphovascular invasion. Our data reveal that MTDH is not a prognostic biomarker in resistant EAC after trimodality therapy.